Evidence map›Paper›PMID 37297026›Full record

ArticleCancers2023

Irinotecan- vs. Oxaliplatin-Based Doublets in KRAS

Vincenzo Formica, Cristina Morelli, Veronica Conca, Maria Alessandra Calegari, Jessica Lucchetti, Emanuela Dell'Aquila, Marta Schirripa, Marco Messina, Lisa Salvatore, Federica Lo Prinzi and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 8 institutions in 2 countries.

Vincenzo FormicaMedical Oncology Unit, Department of Medicine of the Systems, University of Rome Tor Vergata, 00133 Rome, Italy.ORCID 0000-0002-5380-3144
Cristina MorelliMedical Oncology Unit, Department of Medicine of the Systems, University of Rome Tor Vergata, 00133 Rome, Italy.
Veronica ConcaDepartment of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56126 Pisa, Italy.
Maria Alessandra CalegariOncologia Medica, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy.
Jessica LucchettiFondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo, 200, 00128 Rome, Italy.
Emanuela Dell'AquilaRegina Elena National Cancer Institute, Medical Oncology 1, 00144 Rome, Italy.ORCID 0000-0002-7258-1364
Marta SchirripaDepartment of Oncology and Hematology, Belcolle Hospital, Azienda Sanitaria Locale Viterbo, 01100 Viterbo, Italy.
Marco MessinaUOC Oncologia Medica, ARNAS Ospedali Civico Di Cristina Benefratelli, 90127 Palermo, Italy.
Lisa SalvatoreOncologia Medica, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy.ORCID 0000-0003-3864-0719
Federica Lo PrinziFondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo, 200, 00128 Rome, Italy.
Giovanni DimaDepartment of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56126 Pisa, Italy.ORCID 0000-0002-1973-734X
Giovanni TrovatoOncologia Medica, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy.
Silvia RiondinoMedical Oncology Unit, Department of Medicine of the Systems, University of Rome Tor Vergata, 00133 Rome, Italy.ORCID 0000-0002-2965-402X
Mario RoselliMedical Oncology Unit, Department of Medicine of the Systems, University of Rome Tor Vergata, 00133 Rome, Italy.
Ferdinandos SkoulidisDepartment of Thoracic-Head & Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Hendrik-Tobias ArkenauEllipses Pharma, London W1J 8LG, UK.
Chiara CremoliniDepartment of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56126 Pisa, Italy.
University of Rome Tor Vergata · ITUniversity of Pisa · ITCampus Bio Medico University Hospital · ITUniversità Cattolica del Sacro Cuore · ITAgostino Gemelli University Polyclinic · ITAzienda di Rilievo Nazionale ed Alta Specializzazione · ITAzienda Sanitaria Locale Viterbo · ITThe University of Texas MD Anderson Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundKRAS

methodsA multicentre retrospective analysis was conducted including KRAS

resultsOne hundred and four patients treated with irinotecan-(N = 47) or oxaliplatin-based (N = 57) chemotherapy were included. In the unmatched population, objective response rate (ORR) and median (m) progression-free and overall survival (mPFS and mOS) were comparable between the treatment arms. However, a late (>12 months) PFS advantage was observed with irinotecan (HR 0.62,

conclusionsFirst-line irinotecan-based regimens provided better survival results in KRAS

Indexed as

irinotecanKRASG12C mutationmetastatic colorectal canceroxaliplatin

Identifiers

PMID37297026
PMCPMC10252545
OpenAlexW4379519546

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.